(Q37055363)

18 August 2017

1 reference

title

Nanoparticles for drug delivery in cancer treatment (English)

1 reference

18 August 2017

0 references

1 reference

Barbara Haley

1

1 reference

18 August 2017

Eugene Frenkel

series ordinal

2

1 reference

18 August 2017

publication date

1 January 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

26

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

57-64

1 reference

Control of tumour vascular permeability

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Microcirculation of tumors Part I: Anatomy, function, and necrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Vascularization of tumors: A review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Delivery of molecular and cellular medicine to solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Drug delivery and transport to solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Detection of P-glycoprotein in the nuclear envelope of multidrug resistant cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Targeted drug delivery in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Nanoparticles in cancer therapy and diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Emerging use of nanoparticles in diagnosis and treatment of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Transvascular drug delivery in solid tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Targeted drug delivery via the folate receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Nanostructure-mediated drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Nanomedicine: current status and future prospects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Doxorubicin in sterically stabilized liposomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

pH-sensitive liposomes: possible clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Liposomal encapsulated anti-cancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

High affinity binding of paclitaxel to human serum albumin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Interaction of taxol with human serum albumin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

Folate-linked lipid-based nanoparticle for targeted gene delivery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.03.015

10.1016/J.UROLONC.2007.03.015

7 January 2021

Identifiers

DOI

1 reference

18 August 2017

1 reference